Cooper Medical's trading volume on March 6th was $407 million, an increase of 102.90% compared to the previous trading day.

On March 6, 2026, healthcare用品公司 Cooper Medical (COO) had a trading volume of $407 million, ranking 328th among US stocks that day, with a 102.90% increase compared to yesterday, and a trading volume of 5.2975 million.

Cooper Medical (COO) fell 4.55% on March 6, 2026, closing at $76.55. The stock declined 8.51% over the past 5 trading days, and for the entire March, it decreased 8.51%. Year-to-date, it has fallen 6.60%, and over the past 52 weeks, it declined 15.86%.

If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies to listings less than 1 month or fewer than 5 trading days).

Cooper Medical released its Q1 FY2026 earnings report on March 5, 2026. From November 1, 2025, to January 31, 2026, revenue was $1.02B, a 6.16% increase year-over-year, with a net profit of $131 million, up 25.41% year-over-year.

On March 6, 2026, Barclays maintained an “Overweight” rating for Cooper Medical with a target price of $103.

The Cooper Companies, Inc. is a Delaware-incorporated company founded in 1980, and is a global medical device company listed on the NYSE. Cooper operates through two business segments: CooperVision and CooperSurgical. CooperVision is a global manufacturer providing products for contact lens wearers. The company develops, manufactures, and sells various disposable, bi-weekly, and monthly contact lenses made with advanced materials and optical components. Its products are designed to address vision challenges such as astigmatism, presbyopia, myopia, dry eyes, and eye fatigue; it offers a wide range of spherical, toric, and multifocal contact lenses. CooperSurgical offers a broad range of products and services focused on fertility and women’s health.